Citations

Clear

2303 citation(s) found for "Yu, Edward".

Tocolysis for open prenatal repair of myelomeningocele: systematic review
Novoa, Victoria Novoa y, Júnior, Edward Araujo , Tonni, Gabriele , Shazly, Sherif, Araujo Júnior, Edward , Novoa, Victoria Arruga Novoa y, Shazly, Sherif A. , Ruano, Rodrigo

Mayo Clinic

The Journal of Maternal-Fetal & Neonatal Medicine | December 11, 2018 | Volume: 33 | Issue: 10 | Pages: 1786-1791

10.1080/14767058.2018.1528222 | PMID 30526147 Get It

Endoscopic Evaluation of the Eustachian Tube: assessment of a novel tool for grading Eustachian tube inflammation
McCoul, Edward D. , Mayer, Scott, Tabaee, Abtin, Bedrosian, Jeffrey C., Marino, Michael J. , McCoul, Edward D

Mayo Clinic

International Forum of Allergy & Rhinology | November 28, 2018 | Volume: 9 | Issue: 3 | Pages: 305-310

10.1002/alr.22252 | PMID 30485734 Get It

BackgroundSigns of inflammation are commonly encountered during endoscopic examination of the Eustachian tube (ET) region. The clinical applicability of these findings may be enhanced by use of a standardized assessment score.MethodsDigital video recordings were obtained of 50 nasal endoscopy examinations of the nasopharyngeal portion of the ET. Four fellowship‐trained rhinologists independently reviewed the videos with regard to specific physical findings: edema of the ET torus, erythema of the ET torus, exudate at the ET orifice, and presence of tubal tonsil. Scoring of this Endoscopic Evaluation of the Eustachian Tube (3ET) was reported using both 2‐point and 3‐point scales. Each reviewer repeated the scoring at a 10‐day interval. Interrater and intrarater agreement were calculated for each item and the total scores.ResultsInterrater and intrarater agreement were greater for the 3‐point scale than the 2‐point scale. Interrater agreement for overall instrument using the 3‐point scale was in the “acceptable” range for Krippendorff's alpha on both the first trial (0.6922) and second trial (0.7238). Intrarater agreement was generally “excellent” for individual items as well as the overall instrument.ConclusionThe 3ET comprising these 4 physical findings has acceptable interrater and intrarater reliability, and may be applied to future clinical studies of ET function and disease.
Rapamycin improves healthspan but not inflammaging in nfκb1−/− mice
Correia‐Melo, Clara , Birch, Jodie , Fielder, Edward , Rahmatika, Dina , Taylor, Jennifer, Chapman, James , Lagnado, Anthony B. , Carroll, Bernadette , Miwa, Satomi , Richardson, Gavin D. , Jurk, Diana , Oakley, Fiona , Mann, Jelena , Mann, Derek A. , Passos, João F. , Lagnado, Anthony, Jurk, Diana , Passos, João F , Richardson, Gavin D , Taylor, Jennifer, Korolchuk, Viktor I.

Mayo Clinic

Aging Cell | November 23, 2018 | Volume: 18 | Issue: 1 | Pages: No page available

10.1111/acel.12882 | PMID 30468013 Get It

AbstractIncreased activation of the major pro‐inflammatory NF‐κB pathway leads to numerous age‐related diseases, including chronic liver disease (CLD). Rapamycin, an inhibitor of mTOR, extends lifespan and healthspan, potentially via suppression of inflammaging, a process which is partially dependent on NF‐κB signalling. However, it is unknown if rapamycin has beneficial effects in the context of compromised NF‐κB signalling, such as that which occurs in several age‐related chronic diseases. In this study, we investigated whether rapamycin could ameliorate age‐associated phenotypes in a mouse model of genetically enhanced NF‐κB activity (nfκb1−/−) characterized by low‐grade chronic inflammation, accelerated aging and CLD. We found that, despite showing no beneficial effects in lifespan and inflammaging, rapamycin reduced frailty and improved long‐term memory, neuromuscular coordination and tissue architecture. Importantly, markers of cellular senescence, a known driver of age‐related pathology, were alleviated in rapamycin‐fed animals. Our results indicate that, in conditions of genetically enhanced NF‐κB, rapamycin delays aging phenotypes and improves healthspan uncoupled from its role as a suppressor of inflammation.
Guidelines for Perioperative Care in Elective Colorectal Surgery: Enhanced Recovery After Surgery (ERAS ® ) Society Recommendations: 2018
Gustafsson, Ulf , Scott, Michael J. , Hübner, Martin , Demartines, Nicolas , Rockall, Timothy , Young‐Fadok, Tonia M., Soop, Mattias , Boer, Hans D. de , Chang, George J. , Keßler, Hermann, Whang, Edward E. , Fawcett, William , Carli, F. , Lobo, Dileep N. , Rollins, Katie E. , Balfour, Angie , Ljungqvist, Olle , Demartines, N , Lobo, D N , Hübner, Martin , Nygren, Jonas , Francis, Nader Kamal , Hill, Andrew Graham , Urman, Richard D , Fichera, A., Grass, Fabian , Baldini, G., Riedel, Bernhard

Mayo Clinic

World Journal of Surgery | November 13, 2018 | Volume: 43 | Issue: 3 | Pages: 659-695

10.1007/s00268-018-4844-y | PMID 30426190 Get It

Abstract Background This is the fourth updated Enhanced Recovery After Surgery (ERAS ® ) Society guideline presenting a consensus for optimal perioperative care in colorectal surgery and providing graded recommendations for each ERAS item within the ERAS ® protocol. Methods A wide database search on English literature publications was performed. Studies on each item within the protocol were selected with particular attention paid to meta‐analyses, randomised controlled trials and large prospective cohorts and examined, reviewed and graded according to Grading of Recommendations, Assessment, Development and Evaluation (GRADE) system. Results All recommendations on ERAS ® protocol items are based on best available evidence; good‐quality trials; meta‐analyses of good‐quality trials; or large cohort studies. The level of evidence for the use of each item is presented accordingly. Conclusions The evidence base and recommendation for items within the multimodal perioperative care pathway are presented by the ERAS ® Society in this comprehensive consensus review.
Sex‐specific effects of dehydroepiandrosterone (DHEA) on bone mineral density and body composition: A pooled analysis of four clinical trials
Jankowski, Catherine M. , Wolfe, Pamela, Schmiege, Sarah J. , Mühlen, Denise von, Laughlin, Gail A., Bergstrom, Jaclyn , Bettencourt, Richele, Weiss, Edward P., Villareal, Dennis T. , Kohrt, Wendy M., Nair, K. Sreekumaran , Khosla, Sundeep , Jensen, Michael, Kritz‐Silverstein, Donna C.

Mayo Clinic

Clinical Endocrinology | November 13, 2018 | Volume: 90 | Issue: 2 | Pages: 293-300

10.1111/cen.13901 | PMID 30421439 Get It

SummaryObjectiveStudies of dehydroepiandrosterone (DHEA) therapy in older adults suggest sex‐specific effects on bone mineral density (BMD) and body composition, but the ability of a single study to reach this conclusion was limited. We evaluated the effects of DHEA on sex hormones, BMD, fat mass and fat‐free mass in older women and men enrolled in four similar clinical trials.DesignPooled analyses of data from four double‐blinded, randomized controlled trials.ParticipantsWomen (n = 295) and men (n = 290) aged 55 years or older who took DHEA or placebo tablet daily for 12 months.MeasurementsTwelve‐month changes in BMD, fat mass, fat‐free mass and serum DHEA sulphate (DHEAS), (17)estradiol, testosterone and insulin‐like growth factor‐1 (IGF‐1).ResultsWomen on DHEA had increases (mean ± SD; all P < 0.001 vs placebo) in DHEAS (231 ± 164 µg/dL), testosterone (18.6 ± 20.9 µg/dL), (17)estradiol (8.7 ± 11.0 pg/mL) and IGF‐1 (25.1 ± 52.3 ng/mL), and men had increases in DHEAS (269.0 ± 177 µg/dL; P < 0.01), (17)estradiol (4.8 ± 12.2 pg/m; P < 0.01) and IGF‐1 (6.3 ± 41.4 ng/mL; P < 0.05). Women on DHEA had increases in lumbar spine (1.0% ± 3.4%) and trochanter (0.5% ± 3.8%) BMD and maintained total hip BMD (0.0% ± 2.8%); men had no BMD benefit and a decrease in fat mass (−0.4 ± 2.6 kg; all P < 0.01 vs placebo).ConclusionsDehydroepiandrosterone therapy may be an effective approach for preserving bone and muscle mass in women. Key questions are (a) the extent to which longer duration DHEA can attenuate the loss of bone and muscle in women, and (b) whether DHEA has a more favourable benefit‐to‐risk profile for women than oestrogen therapy.
Myeloablative vs reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chronic myeloid leukemia
Chhabra, Saurabh , Ahn, Kwang Woo , Hu, Zhen‐Huan , Jain, Sandeep , Černý, Jan , Copelan, Edward A. , Daly, Andrew , DeFilipp, Zachariah , Gadalla, Shahinaz M. , Ganguly, Siddhartha , Hamilton, Betty K. , Hildebrandt, Gerhard , Hsu, Jack W., Inamoto, Yoshihiro , Kanate, Abraham S. , Khoury, H. Jean, Litzow, Mark R. , Nathan, Sunita , Olsson, Richard F. , Pawarode, Attaphol , Ringdén, Olle , Rowe, Jacob M. , Saad, Ayman , Schouten, Harry C. , Seo, Sachiko , Shah, Nirav N. , Solh, Melhem , Üstün, Celalettin , Woolfrey, Ann E. , Alyea, Edwin P. , Kalaycio, Matt, Sobecks, Ronald , Saber, Wael , Cerny, Jan , Gadalla, Shahinaz M , Nathan, Sunita , Saad, Ayman , Olsson, Richard F , Ringden, Olov , Chhabra, Saurabh , Assal, Amer , Gale, Robert Peter , Lazarus, Hillard M. , Savani, Bipin N. , Stuart, Robert K. , Yared, Jean A. , Popat, Uday R

Mayo Clinic

Blood Advances | November 5, 2018 | Volume: 2 | Issue: 21 | Pages: 2922-2936

10.1182/bloodadvances.2018024844 | PMID 30396912 Get It

Abstract Allogeneic hematopoietic cell transplantation (allo-HCT) is a potentially curative treatment of chronic myeloid leukemia (CML). Optimal conditioning intensity for allo-HCT for CML in the era of tyrosine kinase inhibitors (TKIs) is unknown. Using the Center for International Blood and Marrow Transplant Research database, we sought to determine whether reduced-intensity/nonmyeloablative conditioning (RIC) allo-HCT and myeloablative conditioning (MAC) result in similar outcomes in CML patients. We evaluated 1395 CML allo-HCT recipients between the ages of 18 and 60 years. The disease status at transplant was divided into the following categories: chronic phase 1, chronic phase 2 or greater, and accelerated phase. Patients in blast phase at transplant and alternative donor transplants were excluded. The primary outcome was overall survival (OS) after allo-HCT. MAC (n = 1204) and RIC allo-HCT recipients (n = 191) from 2007 to 2014 were included. Patient, disease, and transplantation characteristics were similar, with a few exceptions. Multivariable analysis showed no significant difference in OS between MAC and RIC groups. In addition, leukemia-free survival and nonrelapse mortality did not differ significantly between the 2 groups. Compared with MAC, the RIC group had a higher risk of early relapse after allo-HCT (hazard ratio [HR], 1.85; P = .001). The cumulative incidence of chronic graft-versus-host disease (cGVHD) was lower with RIC than with MAC (HR, 0.77; P = .02). RIC provides similar survival and lower cGVHD compared with MAC and therefore may be a reasonable alternative to MAC for CML patients in the TKI era.
CADD-57. THE EFFICACY OF THERAPY WITH ABT-414, AN EGFR-TARGETING ADC, IS POTENTIALLY ALTERED BY HETEROZYGOUS DELETION OF THE ENDOCYTIC TRAFFICKING REGULATOR RBSN
Muller-Greven, Gaëlle, Marin, Bianca M. , Carlin, Cathleen R. , Reilly, Edward B. , Bredel, M., Gladson, Candece L. , Marin, Bianca M , Müller-Greven, Gaëlle, Lee, Jeongwu , Sarkaria, Jann N.

Mayo Clinic

Neuro-Oncology | November 5, 2018 | Volume: 20 | Issue: suppl_6 | Pages: vi283-vi284

10.1093/neuonc/noy148.1182 Get It

Patterns of changes in bipolar depressive symptoms revealed by trajectory analysis among 482 patients with bipolar disorder
Behrendt‐møller, Ida , Madsen, Trine , Sørensen, Holger J. , Sylvia, Louisa G. , Friedman, Edward S., Shelton, Richard C. , Bowden, Charles L., Calabrese, Joseph R. , Ketter, Terence A. , Reilly-Harrington, Noreen A. , Gao, Keming , Thase, Michael E., Tohen, Mauricio , McInnis, Melvin G. , Kamali, Masoud , Kocsis, James H., Deckersbach, Thilo , Nierenberg, Andrew A. , Ketter, Terence A , Gao, Keming , V Bobo, William , Tohen, Mauricio , Kamali, Masoud , McInnis, Melvin G , McElroy, Susan L. , Bobo, William V. , Köhler‐Forsberg, Ole

Mayo Clinic

Bipolar Disorders | November 1, 2018 | Volume: 21 | Issue: 4 | Pages: 350-360

10.1111/bdi.12715 | PMID 30383333 Get It

IntroductionDepressive episodes are often prevalent among patients with bipolar disorder, but little is known regarding the differential patterns of development over time. We aimed to determine and characterize trajectories of depressive symptoms among adults with bipolar disorder during 6 months of systematic treatment.MethodsThe pragmatic clinical trial, Bipolar Clinical Health Outcomes Initiative in Comparative Effectiveness (CHOICE), randomized 482 outpatients with bipolar disorder to lithium or quetiapine. Depressive symptoms were rated at up to 9 visits using the Montgomery‐Asberg Depression Rating Scale (MADRS). Growth mixture modeling was utilized to identify trajectories and multinomial regression analysis estimated associations with potential predictors.ResultsFour distinct trajectories of depressive symptoms were identified. The responding class (60.3%) with a rapid reduction and subsequent low level; the partial‐responding class (18.4%) with an initial reduction followed by an increase during the remaining weeks; the fluctuating class (11.6%) with a fluctuation in depressive symptoms; and the non‐responding class (9.7%) with sustained moderate‐severe depressive symptoms. Bipolar type I predicted membership of the non‐responding class and randomization to quetiapine predicted membership of either the responding or the non‐responding class.ConclusionApproximately 30% experienced a partial or fluctuating course, and almost 10% had a chronic course with moderate‐severe depression during 6 months. Patients diagnosed with bipolar type 1 had higher risk of being categorized into a class with a worse outcome. While no differences in average overall outcomes occurred between the lithium and quetiapine groups, trajectory analysis revealed that the lithium group had more variable courses.
The Power of Proficiency Testing: Unraveling Single-Nucleotide Polymorphism Interference, With Potential Impact on Clinical Testing of Spinocerebellar Ataxia Type 3
Lundquist, Patrick A. , Highsmith, W. Edward, Weck, Karen, Ida, Cristiane M. , Weck, Karen E.

Mayo Clinic

Archives of Pathology & Laboratory Medicine | November 1, 2018 | Volume: 143 | Issue: 3 | Pages: 349-355

10.5858/arpa.2017-0566-oa | PMID 30383393 Get It

Context.— The College of American Pathologists proficiency testing program has been instrumental in identifying problems in clinical testing. Objective.— To describe how this program was used to identify a single-nucleotide polymorphism that affects clinical testing for spinocerebellar ataxia type 3. Design.— A proficiency testing sample with discordant results for spinocerebellar ataxia type 3 analysis was further evaluated by targeted Sanger sequencing and genotype polymerase chain reaction using multiple DNA polymerases. Results.— Of 28 laboratories responding in the spinocerebellar ataxia type 3 Proficiency Survey, 18 reported an incorrect homozygous result and 10 reported the expected heterozygous result. A heterozygous single-nucleotide polymorphism complementary to the 3′ end of a published forward primer was identified in the proficiency testing sample, which may have led to allele dropout. However, this primer was used by only 3 of 18 laboratories (16%) reporting a homozygous result. A new forward primer of identical sequence, except for the 3′ end being complementary to the single-nucleotide polymorphism, showed the expected heterozygous pattern. The possibility of DNA polymerase 3′-5′ exonuclease activity contributing to allele dropout was investigated by testing 9 additional polymerases with and without exonuclease activity. No clear pattern emerged, but enzymes with and without 3′-5′ exonuclease activity yielded both homozygous and expected heterozygous results with the published forward primer. Conclusions.— Proactive systematic primer sequence checking is recommended because single-nucleotide polymorphism interference may result in allele dropout and impact clinical testing. Allele dropout is also influenced by other factors, including DNA polymerase exonuclease activity.
Longitudinal Screening Detects Cognitive Stability and Behavioral Deterioration in ALS Patients
Woolley, Susan , Goetz, Ray, Factor‐Litvak, Pam , Murphy, Jennifer , Hupf, Jonathan , Lomen‐Hoerth, Catherine , Andrews, Howard , Heitzman, Daragh, Bedlack, Richard , Katz, Jonathan, Barohn, Richard J., Sorenson, Eric J. , Oskarsson, Björn , Filho, Americo Fernandes, Kasarskis, Edward J. , Mozaffar, Tahseen , Nations, Sharon , Swenson, Andrea , Koczon-Jaremko, Agnes, Christodoulou, Georgia , Mitsumoto, Hiroshi , Garofalo, Diana C. , Sorenson, Eric, Oskarsson, Björn , Bedlack, Richard S , Christodoulou, Georgia

Mayo Clinic

Behavioural Neurology | October 31, 2018 | Volume: 2018 | Issue: No issue available | Pages: 1-7

10.1155/2018/5969137 | PMID 30515252 Get It

Objective. To evaluate longitudinal cognitive/behavioral change over 12 months in participants enrolled in the ALS Multicenter Cohort Study of Oxidative Stress (ALS COSMOS). Methods. We analyzed data from 294 ALS participants, 134 of whom were studied serially. Change over time was evaluated controlling for age, sex, symptom duration, education, race, and ethnicity. Using multiple regression, we evaluated associations among decline in ALS Functional Rating Scale-Revised (ALSFRS-R) scores, forced vital capacity (FVC), and cognitive/behavioral changes. Change in cognitive/behavioral subgroups was assessed using one-way analyses of covariance. Results. Participants with follow-up data had fewer baseline behavior problems compared to patients without follow-up data. We found significant worsening of behavior (ALS Cognitive Behavioral Screen (ALS CBS) behavioral scale, p<0.001; Frontal Behavioral Inventory-ALS (FBI-ALS) disinhibition subscale, p=0.044). Item analysis suggested change in frustration tolerance, insight, mental rigidity, and interests (p<0.05). Changes in ALSFRS-R correlated with the ALS CBS. Worsening disinhibition (FBI-ALS) did not correlate with ALSFRS-R, FVC, or disease duration. Conclusion. We did not detect cognitive change. Behavioral change was detected, and increased disinhibition was found among patients with abnormal baseline behavioral scores. Disinhibition changes did not correlate with disease duration or progression. Baseline behavioral problems were associated with advanced, rapidly progressive disease and study attrition.